National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
niams.nih.govLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
99
Active
13
Phase 3
6
Total enrollment
570,534
Pipeline matrix
Showing 4 of 4 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Doxycycline | — | — | — | — | 2 | ||
| anifrolumab | — | — | — | — | — | 1 | |
| Trimethoprim/sulfamethoxazole | — | — | — | — | — | 1 | |
| Cephalexin | — | — | — | — | — | 1 |
Next readouts
- 2027-01-01
- 2027-08-01
Top conditions
- Rheumatoid Arthritis12
- Systemic Lupus Erythematosus10
- Dermatomyositis6
- Osteoporosis5
- Ankylosing Spondylitis5
- Arthritis4
- Polymyositis4
- Arthritis, Rheumatoid4
Frequently asked questions about National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- How many clinical trials does National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) have on ClinicalTrials.gov?
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is listed as the lead sponsor on 99 clinical trials in ClinicalTrials.gov, 13 of which are currently active (recruiting, enrolling, or ongoing).
- How many of National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)'s trials are in Phase 3?
- 6 of National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)'s trials are in Phase 3, spread across 4 active drug programs.
- What therapeutic areas does National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) focus on?
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)'s most-studied conditions on ClinicalTrials.gov are Rheumatoid Arthritis, Systemic Lupus Erythematosus, Dermatomyositis, Osteoporosis, Ankylosing Spondylitis.
- When are National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)'s next clinical trial readouts?
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) has 2 upcoming primary-completion readouts tracked here; the soonest is “Effects of Treatments on Atopic Dermatitis”, expected around 2027-01-01.